Pharming Group N.V. is a biotechnology business based in the US. Pharming Group N.V. shares (PHAR) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $7.91 – a decrease of 10.72% over the previous week. Pharming Group N.V. employs 382 staff and has a trailing 12-month revenue of around $285.7 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $7.91 |
|---|---|
| 52-week range | $6.65 - $11.94 |
| 50-day moving average | $9.26 |
| 200-day moving average | $8.47 |
| Wall St. target price | $27.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.27 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $8.0501 from 2025-03-07
| 1 week (2025-03-06) | -3.82% |
|---|---|
| 1 month (2025-02-13) | -9.00% |
| 3 months (2024-12-13) | -10.38% |
| 6 months (2024-09-13) | 7.33% |
| 1 year (2024-03-12) | -32.24% |
|---|---|
| 2 years (2023-03-10) | -31.78% |
| 3 years (2022-03-11) | 8.522 |
| 5 years (2020-03-09) | N/A |
| Revenue TTM | $285.7 million |
|---|---|
| Operating margin TTM | 5.49% |
| Gross profit TTM | $255.4 million |
| Return on assets TTM | -1.38% |
| Return on equity TTM | -8.18% |
| Profit margin | -6.24% |
| Book value | $0.44 |
| Market Capitalization | $560.7 million |
TTM: trailing 12 months
We're not expecting Pharming Group N.V. to pay a dividend over the next 12 months.
You may also wish to consider:
Over the last 12 months, Pharming Group N.V.'s shares have ranged in value from as little as $6.65 up to $11.94. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Pharming Group N.V.'s is 0.639. This would suggest that Pharming Group N.V.'s shares are less volatile than average (for this exchange).
To put Pharming Group N.V.'s beta into context you can compare it against those of similar companies.
Pharming Group N. V. , a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.
Spot dogecoin ETFs might soon be approved. Here’s how to invest if and when they become available to trade.
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
We analyzed a number of bitcoin ETFs to determine which are best to invest in.
Arrived offers a simple way to invest in real estate rental properties.
3 Northwestern Mutual wealth management alternatives to consider.
Investing in mutual funds offers instant diversification. Learn more.
What you need to know about investing in the leading indicator for the overall US stock market.
Here’s what you need to know about how to buy and sell stocks online in this easy to follow, step-by-step guide.